• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
GSK-461364

GSK-461364

Product ID G7241
Cas No. 929095-18-1
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $127.90 In stock
5 mg $216.20 In stock
10 mg $337.60 In stock
25 mg $601.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

GSK-461364 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for solid tumor cancers. GSK-461364 displays anticancer chemotherapeutic activity as well as anticoagulant activity. This compound inhibits glioblastoma cell proliferation, invasion, and colony formation and induces apoptosis and G2 phase cell cycle arrest.

Product Info

Cas No.

929095-18-1

Purity

≥99%

Formula

C27H28F3N5O2S

Formula Wt.

543.60

IUPAC Name

5-{6-[(4-Methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl}-3-{(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy}-2-thiophenecarboxamide

Solubility

Ethanol 30 mg/mL (55.18 mM) DMSO 10 mg/mL (18.39 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

G7241 MSDS PDF

Info Sheet

G7241 Info Sheet PDF

References

Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 2013 Nov;24(10):999-1006. PMID: 23949254.

Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther. 2013 Sep;20(9):499-506. PMID: 23887645.

Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. PMID: 21459796.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T0116

    2″,3″-Dihydrocephalomannine

    Cephalomannine derivative found in Taxus; poten...

    ≥96%
  • I5208

    INCB-28060

    c-MET inhibitor.

    ≥98%
  • I8618

    Ivermectin

    Avermectin; glu-gated Cl- channel activator, Gl...

    ≥95%
  • A4577

    Alsterpaullone

    GSK-3 and CDK inhibitor.

    ≥98%
  • L1786

    Levofloxacin Hydrochloride Monohydrate

    Fluoroquinolone, S-(-) isomer of ofloxacin; top...

    ≥90%
  • D582705

    Dorsomorphin Dihydrochloride

    Inhibitor of ALK2, ALK3, ALK6, and AMPK.

    ≥98%
  • P1770

    Perillyl Alcohol

    Terpene found in various plant and fruit source...

    ≥85%
  • A480000

    AM251

    CB1 receptor antagonist/ inverse agonist.

    ≥97%
  • O7218

    Oseltamivir Phosphate

    Viral neuraminidase inhibitor, potential MAO-A ...

    ≥98%
  • H0002

    H8 dihydrochloride

    PKA inhibitor.

    ≥98%
  • K0144

    Kallikrein Inhibitor

    Peptide; serine protease inhibitor.

    ≥95%
  • T1670

    Terazosin Hydrochloride Dihydrate

    Quinazoline; α1-adrenergic antagonist.

    ≥98%
  • A5132

    Amikacin Disulfate

    Aminoglycoside; protein translation inhibitor.<...

    ≥98%
  • A4850

    [His18]-Amylin, rat

    Endogenous peptide hormone inolved in gastric e...

    ≥95%
  • R1779

    13-cis-Retinoic Acid

    Vitamin A metabolite, differentiation inducer; ...

    97%
  • M3584

    Mivacurium

    Non-depolarizing NMJ blocker; nAChR antagonist....

    ≥98%
  • N3478

    Nitrendipine

    Calcium channel blocker.

    ≥98%
  • H0169

    Harringtonine

    Cephalotaxine alkaloid originally found in Ceph...

    ≥98%
  • A5472

    Ansamitocin P3

    Microtubule depolymerization inhibitor.

    ≥70% (P3), Total Ansamitocins ≥95%
  • P2815

    Phenylbutyrate Sodium

    HDAC inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only